| 1 |
Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Non-amyloid Logopenic Variant
|
|
|
|
In: ISSN: 0028-3878 ; EISSN: 1526-632X ; Neurology ; https://hal.archives-ouvertes.fr/hal-03281660 ; Neurology, American Academy of Neurology, 2021, ⟨10.1212/wnl.0000000000012174⟩ (2021)
|
|
BASE
|
|
Show details
|
|
|
| 2 |
A Reliable and Rapid Language Tool for the Diagnosis, Classification, and Follow-Up of Primary Progressive Aphasia Variants
|
|
|
|
In: Front Neurol (2021)
|
|
BASE
|
|
Show details
|
|
|
| 3 |
Accuracy of MRI classification algorithms in a tertiary memory center clinical routine cohort
|
|
|
|
In: AAIC 2017 - Alzheimer's Association International Conference ; https://hal.archives-ouvertes.fr/hal-02192444 ; AAIC 2017 - Alzheimer's Association International Conference, Jul 2017, London, United Kingdom. pp.P772-P774, ⟨10.1016/j.jalz.2017.06.1034⟩ (2017)
|
|
BASE
|
|
Show details
|
|
|
| 4 |
Free and Cued Selective Reminding Test – accuracy for the differential diagnosis of Alzheimer's and neurodegenerative diseases: A large-scale biomarker-characterized monocenter cohort study (ClinAD)
|
|
|
|
In: ISSN: 1552-5260 ; Alzheimer's and Dementia ; https://hal.inria.fr/hal-01672862 ; Alzheimer's and Dementia, Elsevier, 2017, 13 (8), pp.913 - 923. ⟨10.1016/j.jalz.2016.12.014⟩ (2017)
|
|
BASE
|
|
Show details
|
|
|
| 5 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 6 |
Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
|
|
|
|
In: Alzheimer's & dementia : the journal of the Alzheimer's Association, vol 12, iss 3 (2016)
|
|
BASE
|
|
Show details
|
|
|
| 7 |
Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria
|
|
Dubois, Bruno; Hampel, Harald; Feldman, Howard H.; Scheltens, Philip; Aisen, Paul; Andrieu, Sandrine; Bakardjian, Hovagim; Benali, Habib; Bertram, Lars; Blennow, Kaj; Broich, Karl; Cavedo, Enrica; Crutch, Sebastian; Dartigues, Jean-François; Duyckaerts, Charles; Epelbaum, Stéphane; Frisoni, Giovanni B.; Gauthier, Serge; Genthon, Remy; Gouw, Alida A.; Habert, Marie-Odile; Holtzman, David M.; Kivipelto, Miia; Lista, Simone; Molinuevo, José-Luis; O’Bryant, Sid E.; Rabinovici, Gil D.; Rowe, Christopher; Salloway, Stephen; Schneider, Lon S.; Sperling, Reisa; Teichmann, Marc; Carrillo, Maria C.; Cummings, Jeffrey; Jack, Cliff R.. - 2016
|
|
Abstract:
During the past decade, a conceptual shift occurred in the field of Alzheimer’s disease (AD) considering the disease as a continuum. Thanks to evolving biomarker research and substantial discoveries, it is now possible to identify the disease even at the preclinical stage before the occurrence of the first clinical symptoms. This preclinical stage of AD has become a major research focus as the field postulates that early intervention may offer the best chance of therapeutic success. To date, very little evidence is established on this “silent” stage of the disease. A clarification is needed about the definitions and lexicon, the limits, the natural history, the markers of progression, and the ethical consequence of detecting the disease at this asymptomatic stage. This article is aimed at addressing all the different issues by providing for each of them an updated review of the literature and evidence, with practical recommendations.
|
|
Keyword:
Article
|
|
URL: https://doi.org/10.1016/j.jalz.2016.02.002
http://www.ncbi.nlm.nih.gov/pubmed/27012484
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6417794/
|
|
BASE
|
|
Hide details
|
|
|
|
|
